Clinical applications of pharmacogenomics

Indexación: Scopus.Pharmacogenomics is an emergent field aimed at tailoring pharmacological therapy. Genetic polymorphisms can modify the expression and function of enzymes and proteins involved in drug metabolism, affecting absorption, distribution, biotransformation and excretion as well as the drug-target interaction. Therefore, the presence of allelic variants will classify people as poor, extensive or rapid/ultra rapid metabolizers, modifying drug efficacy and safety. In this work, the state of art in relation to this discipline is presented and the genetic variants of enzymes that are involved in drug pharmacokinetics or pharmacodynamics are described. The effects of these variants on the therapeutic response to drugs used in our country are also discussed.http://ref.scielo.org/4y6n8

HPLC method for quantification of oxidative stress by salicilate hydroxylation in human plasma

The aim of the present study was to modify and validate a highperformance liquid chromatographic (HPLC) method for determining 2,3 and 2,5 di hydroxy benzoic acid (2,3-DHBA and 2,5-DHBA) from salicylic acid in human plasma. The mobile phase was a mixture of sodium acetate/citrate (pH 2.5) 30 mM-methanol (93:7, v/v). The injection volume was 10 ?L. Retention time for 2,5-DHBA, and 2,3-DHBA was 4.5 � 0.10 and 5.8 � 0.15 min, respectively. The detection and quantification limits were 10 and 40 nM for 2,3-DHBA and 8 and 20 nM for 2,5-DHBA. Linearity was evaluated in the range of 40-1600 nM for both metabolites. Interand intra-analysis variation coefficient was below 10%. Good recoveries of more than 99% were obtained for both metabolites using this method

HPLC method for quantification of oxidative stress by salicilate hydroxylation in human plasma

The aim of the present study was to modify and validate a highperformance liquid chromatographic (HPLC) method for determining 2,3 and 2,5 di hydroxy benzoic acid (2,3-DHBA and 2,5-DHBA) from salicylic acid in human plasma. The mobile phase was a mixture of sodium acetate/citrate (pH 2.5) 30 mM-methanol (93:7, v/v). The injection volume was 10 μL. Retention time for 2,5-DHBA, and 2,3-DHBA was 4.5 ± 0.10 and 5.8 ± 0.15 min, respectively. The detection and quantification limits were 10 and 40 nM for 2,3-DHBA and 8 and 20 nM for 2,5-DHBA. Linearity was evaluated in the range of 40-1600 nM for both metabolites. Interand intra-analysis variation coefficient was below 10%. Good recoveries of more than 99% were obtained for both metabolites using this method